MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 573206 | Name: Apremilast, (+/-)-

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Apremilast, (+/-)-, also known as Otezla, is an orally administered, small molecule inhibitor of phosphodiesterase 4 (PDE4). Apremilast is effective in the treatment of psoriatic arthritis.

Chemical Structure

Apremilast, (+/-)-
Apremilast, (+/-)-
CAS#253168-86-4

Theoretical Analysis

MedKoo Cat#: 573206

Name: Apremilast, (+/-)-

CAS#: 253168-86-4

Chemical Formula: C22H24N2O7S

Exact Mass: 460.1304

Molecular Weight: 460.50

Elemental Analysis: C, 57.38; H, 5.25; N, 6.08; O, 24.32; S, 6.96

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Apremilast (+/-)-,
IUPAC/Chemical Name
Acetamide, N-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl)-
InChi Key
IMOZEMNVLZVGJZ-UHFFFAOYSA-N
InChi Code
1S/C22H24N2O7S/c1-5-31-19-11-14(9-10-18(19)30-3)17(12-32(4,28)29)24-21(26)15-7-6-8-16(23-13(2)25)20(15)22(24)27/h6-11,17H,5,12H2,1-4H3,(H,23,25)
SMILES Code
CCOc1cc(ccc1OC)C(CS(=O)(=O)C)N2C(=O)c3cccc(c3C2=O)NC(=O)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 460.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Ohtsuki M, Okubo Y, Komine M, Imafuku S, Day RM, Chen P, Petric R, Maroli A, Nemoto O. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial. J Dermatol. 2017 Aug;44(8):873-884. doi: 10.1111/1346-8138.13829. Epub 2017 Apr 9. PubMed PMID: 28391657; PubMed Central PMCID: PMC5573969. 2: Reed M, Crosbie D. Apremilast in the treatment of psoriatic arthritis: a perspective review. Ther Adv Musculoskelet Dis. 2017 Feb;9(2):45-53. doi: 10.1177/1759720X16673786. Epub 2017 Jan 20. Review. PubMed PMID: 28255338; PubMed Central PMCID: PMC5315225. 3: Keating GM. Apremilast: A Review in Psoriasis and Psoriatic Arthritis. Drugs. 2017 Mar;77(4):459-472. doi: 10.1007/s40265-017-0709-1. Review. PubMed PMID: 28213862. 4: Mayba JN, Gooderham MJ. Real-World Experience With Apremilast in Treating Psoriasis. J Cutan Med Surg. 2017 Mar/Apr;21(2):145-151. doi: 10.1177/1203475416676030. Epub 2016 Oct 23. PubMed PMID: 27846617. 5: Reich K, Gooderham M, Green L, Bewley A, Zhang Z, Khanskaya I, Day RM, Goncalves J, Shah K, Piguet V, Soung J. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE). J Eur Acad Dermatol Venereol. 2017 Mar;31(3):507-517. doi: 10.1111/jdv.14015. Epub 2016 Dec 19. PubMed PMID: 27768242; PubMed Central PMCID: PMC5363370. 6: Cutolo M, Myerson GE, Fleischmann RM, Lioté F, Díaz-González F, Van den Bosch F, Marzo-Ortega H, Feist E, Shah K, Hu C, Stevens RM, Poder A. A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial. J Rheumatol. 2016 Sep;43(9):1724-34. doi: 10.3899/jrheum.151376. Epub 2016 Jul 15. PubMed PMID: 27422893. 7: AbuHilal M, Walsh S, Shear N. Use of Apremilast in Combination With Other Therapies for Treatment of Chronic Plaque Psoriasis: A Retrospective Study. J Cutan Med Surg. 2016 Jul;20(4):313-6. doi: 10.1177/1203475416631328. Epub 2016 Feb 4. PubMed PMID: 26848145. 8: Edwards CJ, Blanco FJ, Crowley J, Birbara CA, Jaworski J, Aelion J, Stevens RM, Vessey A, Zhan X, Bird P. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis. 2016 Jun;75(6):1065-73. doi: 10.1136/annrheumdis-2015-207963. Epub 2016 Jan 20. PubMed PMID: 26792812; PubMed Central PMCID: PMC4893110. 9: Deeks ED. Apremilast: A Review in Psoriasis and Psoriatic Arthritis. Drugs. 2015 Aug;75(12):1393-403. doi: 10.1007/s40265-015-0439-1. Review. PubMed PMID: 26220911.

View History

AF10

AF10